Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
|Articles|July 29, 2019
Comparison between aberration neutral and negatively aberrated toric IOLs
Author(s)Julianne Mobilian
ICYMI: Dr. Packer shares the pearls from his 2019 ASCRS presentation
Advertisement
Mark Packer, MD, shares the take-home points from the presentation he delivered at the 2019 meeting of the
Advertisement
Related to this article
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
3
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
4
Women’s Health: Identifying dry eye in rheumatoid arthritis can make all the difference
5